Sonic Incytes Announces Multi-Year Partnership with Madrigal Pharmaceuticals to Advance Non-Invasive Liver Assessment in MASH
Sonic Incytes and Madrigal Pharmaceuticals (MDGL) announced a multi-year partnership to advance non-invasive liver assessment for MASH. Sonic Incytes' Velacur platform will be used to help clinicians assess and risk-stratify patients. The partnership aims to expand the use of non-invasive tests at the point of care, with a focus on gastroenterology, hepatology, and endocrinology settings.
How this was made

The 30-second read
Why it matters
The partnership aims to expand use of non-invasive tests at the point of care, potentially improving earlier identification and risk stratification of patients at risk for MASH.
Market read
For MDGL, the news is a diagnostic workflow partnership that could support patient identification for MASH care, but it provides no financial metrics or near-term milestones.
What to watch
Diagnostic adoption depends on clinician uptake, payer reimbursement, and integration into existing workflows; these constraints are not addressed in the article.
Background
MASH is described as significantly underdiagnosed, with limited community access to liver elastography contributing to delayed assessment.
Ticker impact
Madrigal (MDGL) enters a multi-year partnership with Sonic Incytes to expand point-of-care non-invasive MASH liver assessment using Velacur.
Likely modest positive bias as investors view improved diagnostic access as incremental demand support for MASH treatment adoption.
The article is a product-adoption partnership rather than a financial disclosure, but it directly links MDGL’s MASH focus to broader clinical use of a diagnostic tool.
Market effects
Reinforces the MASH ecosystem shift toward non-invasive, point-of-care diagnostics to address underdiagnosis.
No specific regional market impact beyond US clinical adoption framing.
Could support broader global adoption of non-invasive liver assessment approaches, but the article is US-focused.
Counterpoint
Without disclosed commercial terms, reimbursement coverage, or adoption targets, the partnership may have limited near-term revenue impact.
Key entities
- companySonic Incytes Medical Corp.
Developer of the Velacur point-of-care liver assessment platform (Velacur/Velacur ONE).
- companyMadrigal Pharmaceuticals, Inc.
MASH-focused biopharmaceutical company (Nasdaq: MDGL) with an approved therapy and pipeline.
- productVelacur™ / Velacur ONE
AI-guided ultrasound elastography device for point-of-care liver stiffness and fat fraction-related measures (including VDFF).
